Skip to main content

Amyotropic Lateral Sclerosis (ALS) clinical trials at UCSF

5 in progress, 3 open to eligible people

Showing trials for
  • ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

    open to eligible people ages 18 years and up

    ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

    San Francisco, California and other locations

  • ECoG BMI for Motor and Speech Control

    open to eligible people ages 21 years and up

    Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.

    San Francisco, California

  • Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

    open to eligible people ages 18 years and up

    REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS. Epigenetic and protein biomarkers will also be investigated.

    San Francisco, California and other locations

  • A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

    Sorry, not currently recruiting here

    A phase 2 double-blind, placebo-controlled study of AL001 in participants with C9orf72-associated ALS.

    San Francisco, California and other locations

  • An Efficacy and Safety Study of Ravulizumab in ALS Participants

    Sorry, in progress, not accepting new patients

    The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS.

    San Francisco, California and other locations

Last updated: